{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:13:31Z","timestamp":1783498411443,"version":"3.55.0"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease affecting peripheral and axial joints, entheses, skin, and nails, requiring coordinated multidisciplinary management. Since the 2018 edition of ESPOGU\u00cdA, significant advances\u2014including the availability of IL-17A\/F, IL-23, and JAK inhibitors, as well as emerging evidence regarding axial PsA\u2014have prompted the need for an updated guideline. The 2024 ESPOGU\u00cdA provides evidence-based recommendations for the diagnosis and management of PsA, integrating multidisciplinary collaboration, active nursing participation, lifestyle counseling, and specific considerations for axial disease. A panel comprising rheumatologists, dermatologists, gastroenterologists, ophthalmologists, nurses, methodologists, and patient representatives formulated clinical questions using the Population, Intervention, Comparator, and Outcomes (PICO) framework. Systematic literature reviews were performed, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was applied to critically assess the quality of evidence and guide the formulation of recommendations. The guideline emphasizes early intervention and the appropriate use of conventional synthetic DMARDs, biologic therapies, and JAK inhibitors across different disease domains, including the management of extra-musculoskeletal manifestations. Lifestyle measures, such as smoking cessation and weight management, are highlighted due to their demonstrated impact on disease activity and long-term outcomes. The essential role of specialized rheumatology nurses in patient education, treatment adherence, and counseling on modifiable risk factors is also underscored. ESPOGU\u00cdA 2024 provides a comprehensive, multidisciplinary, and patient-centered framework for PsA management, including axial involvement, and identifies persistent gaps in early diagnosis, biomarker development, and long-term outcomes, thereby outlining priorities for future research<\/jats:p>","DOI":"10.1177\/1759720x261436463","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T12:07:33Z","timestamp":1776514053000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis and therapeutic management of psoriatic arthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA)"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7047-8056","authenticated-orcid":false,"given":"Julio","family":"Ram\u00edrez","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednic and IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-5837","authenticated-orcid":false,"given":"Clementina","family":"L\u00f3pez-Medina","sequence":"additional","affiliation":[{"name":"Hospital Reina Sof\u00eda, IMIBIC, University of C\u00f3rdoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-2868","authenticated-orcid":false,"given":"Carlos","family":"Montilla","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of the University of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Moreno","sequence":"additional","affiliation":[{"name":"Parc Taul\u00ed Research and Innovation Institute (I3PT), Hospital Parc Taul\u00ed and Universidad Aut\u00f3noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel J.","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Virgen de la Arrixaca, Biomedical Research Institute of Murcia Pascual Parrilla\u2013IMIB, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[{"name":"Hospital La Paz, IdiPaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Fern\u00e1ndez-Clotet","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Riera-Monroig","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"D\u00edaz-del Campo","sequence":"additional","affiliation":[{"name":"Spanish Society of Rheumatology (SER), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[{"name":"Rheumatology Dpt, Hospital Clinic and IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[{"name":"Rheumatology and ISPA Translational Immunology Division, Central University Hospital of Asturias, Avenida de Roma, S\/N, Oviedo 33011, Spain"},{"name":"Oviedo University School of Medicine, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"e_1_3_4_5_2","volume-title":"Actualizaci\u00f3n","author":"Sociedad Espa\u00f1ola de Reumatolog\u00eda","year":"2024","unstructured":"Sociedad Espa\u00f1ola de Reumatolog\u00eda. Grupo de trabajo ESPOGU\u00cdA. Gu\u00eda de pr\u00e1ctica cl\u00ednica para el tratamiento de la espondiloartritis axial y la artritis psori\u00e1sica. Actualizaci\u00f3n. Madrid: Sociedad Espa\u00f1ola de Reumatolog\u00eda, 2024."},{"issue":"10235","key":"e_1_3_4_6_2","first-page":"1496","article-title":"A head-to-head comparison of secukinumab and adalimumab in patients with psoriatic arthritis: EXCEED trial results","volume":"395","author":"Mease PJ","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of secukinumab and adalimumab in patients with psoriatic arthritis: EXCEED trial results. Lancet 2020; 395(10235): 1496\u20131505.","journal-title":"Lancet"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40851"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00801-8"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090449"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.131237"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22404"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg217"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06589-y"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614255"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000445"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0898-2"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02549-0"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70181"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393463"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"},{"issue":"5","key":"e_1_3_4_28_2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian E","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2022; 5(5): CD011535.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222020"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202296"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1699-258X(07)73690-2"},{"issue":"5","key":"e_1_3_4_32_2","first-page":"284","article-title":"Consensus statement of the Spanish society of rheumatology on risk management of biologic therapy in rheumatic patients","volume":"7","author":"G\u00f3mez Reino J","year":"2011","unstructured":"G\u00f3mez Reino J, Loza E, Andreu JL, et al. Consensus statement of the Spanish society of rheumatology on risk management of biologic therapy in rheumatic patients. Reumatol Clin 2011; 7(5): 284\u2013298.","journal-title":"Reumatol Clin"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.12353"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06520-z"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200185"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320904295"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2022.08.005"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead621"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00722-w"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224148"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901"}],"updated-by":[{"DOI":"10.1177\/1759720x261468104","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000}}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261436463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X261436463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261436463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:39:58Z","timestamp":1780724398000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X261436463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["10.1177\/1759720X261436463"],"URL":"https:\/\/doi.org\/10.1177\/1759720x261436463","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"1759720X261436463"}}